CN109843857B - Ppar激动剂化合物的结晶和盐形式 - Google Patents
Ppar激动剂化合物的结晶和盐形式 Download PDFInfo
- Publication number
- CN109843857B CN109843857B CN201780062034.5A CN201780062034A CN109843857B CN 109843857 B CN109843857 B CN 109843857B CN 201780062034 A CN201780062034 A CN 201780062034A CN 109843857 B CN109843857 B CN 109843857B
- Authority
- CN
- China
- Prior art keywords
- disease
- compound
- syndrome
- compounds
- muscular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| US62/404,474 | 2016-10-05 | ||
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109843857A CN109843857A (zh) | 2019-06-04 |
| CN109843857B true CN109843857B (zh) | 2023-01-06 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780062034.5A Active CN109843857B (zh) | 2016-10-05 | 2017-10-05 | Ppar激动剂化合物的结晶和盐形式 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (enExample) |
| EP (1) | EP3523283B1 (enExample) |
| JP (1) | JP7017563B2 (enExample) |
| KR (1) | KR20190057129A (enExample) |
| CN (1) | CN109843857B (enExample) |
| AU (1) | AU2017340763B2 (enExample) |
| CA (1) | CA3036587A1 (enExample) |
| CO (1) | CO2019003162A2 (enExample) |
| CY (1) | CY1124655T1 (enExample) |
| DK (1) | DK3523283T3 (enExample) |
| ES (1) | ES2887008T3 (enExample) |
| HR (1) | HRP20211341T1 (enExample) |
| HU (1) | HUE055678T2 (enExample) |
| IL (1) | IL265730B (enExample) |
| JO (1) | JOP20190039B1 (enExample) |
| LT (1) | LT3523283T (enExample) |
| MA (1) | MA46460A (enExample) |
| MX (1) | MX385973B (enExample) |
| MY (1) | MY202008A (enExample) |
| PH (1) | PH12019500727A1 (enExample) |
| PL (1) | PL3523283T3 (enExample) |
| PT (1) | PT3523283T (enExample) |
| RS (1) | RS62245B1 (enExample) |
| RU (1) | RU2759724C2 (enExample) |
| SG (1) | SG11201901995TA (enExample) |
| SI (1) | SI3523283T1 (enExample) |
| TW (1) | TWI769182B (enExample) |
| UA (1) | UA124770C2 (enExample) |
| WO (1) | WO2018067860A1 (enExample) |
| ZA (1) | ZA201901744B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109843857B (zh) | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| CN112714762A (zh) * | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| JP7397491B2 (ja) * | 2018-10-23 | 2023-12-13 | 国立研究開発法人科学技術振興機構 | ＰＰＡＲδ活性化剤 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2022256540A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2025207099A1 (en) * | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101072557A (zh) * | 2004-12-17 | 2007-11-14 | 塞诺菲-安万特德国有限公司 | Ppar激动剂用于治疗充血性心力衰竭的用途 |
| CN101141957A (zh) * | 2005-02-03 | 2008-03-12 | Irm责任有限公司 | 作为ppar调节剂的化合物和组合物 |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| CN102300847A (zh) * | 2008-12-23 | 2011-12-28 | 拜欧珐姆德有限责任公司 | Ppar激动剂组合物及其使用方法 |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241157A1 (en) | 2003-01-06 | 2006-10-26 | Conner Scott E | Heterocyclic ppar modulators |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109843857B (zh) | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| UA124019C2 (uk) * | 2016-10-05 | 2021-07-07 | Мітобрідж, Інк. | Спосіб лікування гострого пошкодження нирок |
-
2017
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Ceased
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 MX MX2019003945A patent/MX385973B/es unknown
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en not_active Ceased
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101072557A (zh) * | 2004-12-17 | 2007-11-14 | 塞诺菲-安万特德国有限公司 | Ppar激动剂用于治疗充血性心力衰竭的用途 |
| CN101141957A (zh) * | 2005-02-03 | 2008-03-12 | Irm责任有限公司 | 作为ppar调节剂的化合物和组合物 |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| CN102300847A (zh) * | 2008-12-23 | 2011-12-28 | 拜欧珐姆德有限责任公司 | Ppar激动剂组合物及其使用方法 |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912681B2 (en) | Crystalline and salt forms of PPAR agonist compounds | |
| CN113004205B (zh) | Ppar激动剂、化合物、药物组合物及其使用方法 | |
| JP2022521825A (ja) | アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法 | |
| TWI592407B (zh) | 飢餓素ｏ－醯基轉移酶抑制劑 | |
| CN118388473A (zh) | Fxr激动剂的固体形式 | |
| HK40006508B (en) | Crystalline and salt forms of ppar agonist compounds | |
| HK40006508A (en) | Crystalline and salt forms of ppar agonist compounds | |
| BR112019006030B1 (pt) | Formas cristalinas e de sal de compostos agonistas de ppar e seus usos | |
| EA039771B1 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| WO2005095364A1 (ja) | フェノキシ酢酸誘導体及びそれを用いた医薬 | |
| HK40054571A (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| HK40054571B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| HK40054101A (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| HK40054101B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| CN1938287A (zh) | 苯氧基乙酸衍生物和包含其的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40006508 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |